IDYANasdaqPharmaceutical PreparationsFiscal year ends December 31

IDEAYA Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$33.81+0.96 (+2.92%)

Close on Oct 19, 2026

Market cap: $3.11B
P/E (TTM): –
Dividend yield: –

IDEAYA Biosciences, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Cash & Equivalents	113	85	157	69	92	72	34	21	6.03	9.69
Short-Term Investments	527	592	368	296	155	212	65	69	–	–
Cash & Short-Term Investments	639	677	525	365	247	284	99	90	6.03	9.69
Receivables	–	0.00	0.02	0.21	1.10	1.88	–	–	–	–
Prepaid Expenses & Other	21	13	7.50	5.41	3.12	3.14	2.70	0.71	–	–
Total Current Assets	667	690	533	370	251	289	102	91	–	–
Property, Plant & Equipment	8.22	8.97	6.16	6.51	4.76	4.27	4.64	5.15	–	–
Gross Property, Plant & Equipment	22	21	16	14	10	8.17	7.16	6.44	–	–
Accumulated Depreciation	-14	-12	-9.61	-7.55	-5.60	-3.89	-2.52	-1.28	–	–
Long-Term Investments	410	406	107	8.32	121	0	1.53	–	–	–
Operating Lease Right-of-Use Assets	23	19	2.25	2.48	3.90	5.21	5.06	6.10	–	–
Other Long-Term Assets	–	–	0.03	0.10	0.29	0.08	0.02	0.05	–	–
Total Assets	1,109	1,124	649	388	381	298	113	97	–	–
Accounts Payable	18	15	6.60	4.28	2.10	0.95	0.71	1.42	–	–
Accrued Expenses	41	30	19	17	12	8.52	5.02	3.58	–	–
Current Portion of Leases	0.34	0.30	1.75	1.87	1.70	1.54	1.15	–	–	–
Deferred Revenue (Current)	–	–	–	8.57	29	28	–	–	–	–
Other Current Liabilities	–	–	–	–	–	0.02	0.06	0.11	–	–
Total Current Liabilities	59	46	27	32	45	39	6.94	5.41	–	–
Long-Term Leases	28	19	1.13	1.61	3.48	5.18	5.63	–	–	–
Operating Lease Liabilities	28	19	2.87	3.48	5.18	6.72	6.77	8.00	–	–
Other Long-Term Liabilities	–	–	–	–	–	0.01	0.03	0.11	–	–
Total Liabilities	86	65	28	39	80	100	13	7.10	–	–
Common Stock	0.01	0.01	0.01	0.01	0.00	0.00	0.00	–	–	–
Additional Paid-In Capital	1,757	1,681	969	588	479	325	193	1.60	–	–
Retained Earnings	-737	-623	-348	-235	-177	-127	-92	-51	–	–
Comprehensive Income & Other	2.27	0.81	0.56	-2.87	-0.71	0.01	0.07	-0.03	–	–
Shareholders' Equity	1,023	1,059	621	349	302	198	100	-49	-16	-4.13
Total Equity	1,023	1,059	621	349	302	198	100	-49	-16	-4.13
Total Liabilities & Equity	1,109	1,124	649	388	381	298	113	97	–	–
Shares Outstanding(shares)	88	87	65	48	39	30	20	1.34	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -92.7%
Net margin: -74.8%
Return on equity, FY2025: -10.9%

Financial strength

Current ratio: 10.45
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 329.7%

Valuation

P/E ratio: –
Price to sales: 13.29
Price to book: 2.60
Dividend yield: –